Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Blood (2022) 140 (Supplement 1): 1346–1349.

https://doi.org/10.1182/blood-2022-168521

Published: 2022

Journal Articles

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Blood (2022) 140 (Supplement 1): 10185–10188.

https://doi.org/10.1182/blood-2022-162336

Published: 2022

Journal Articles

Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

Jakob D. Rudzki, Ulrich Jaeger, Dominik Wolf, Andreas Petzer, Richard Greil, Christina Peters, Hildegard T. Greinix, Andishe Attarbaschi, Veronika Buxhofer-Ausch, Michael Girschikofsky, Wolfgang Holter, Michael Leisch, Peter Neumeister, Peter Schlenke, Clemens A. Schmitt, Wolfgang Schwinger, Nina Worel, Philipp Wohlfarth

Blood (2022) 140 (Supplement 1): 6661–6663.

https://doi.org/10.1182/blood-2022-167603

Published: 2022

Journal Articles

SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma

Blood (2022) 139 (4): 538–553.

https://doi.org/10.1182/blood.2021012081

Published: 2022

Includes: Supplemental data

Journal Articles

Therapy-Induced Senescence As an Anti-Cancer and Immune-Stimulatory Strategy

Diego Gilioli, Simona Fusco, Kety Giannetti, Valentina Gambacorta, Teresa Tavella, Carmine Liberatore, Stefano Beretta, Martin Schönlein, Ivan Merelli, Fabio Ciceri, Luca Vago, Clemens A. Schmitt, Raffaella Di Micco

Blood (2021) 138 (Supplement 1): 4419.

https://doi.org/10.1182/blood-2021-152618

Published: 2021

Journal Articles

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

Blood (2021) 138 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2021-145401

Published: 2021

Journal Articles

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Blood (2021) 138 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2021-150311

Published: 2021

Journal Articles

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

Blood (2021) 137 (20): 2785–2799.

https://doi.org/10.1182/blood.2020005244

Published: 2021

Includes: Supplemental data

Journal Articles

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140918

Published: 2020

Journal Articles

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-140701

Published: 2020

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Blood (2019) 134 (Supplement_1): 3821.

https://doi.org/10.1182/blood-2019-128153

Published: 2019

Journal Articles

Senescence Markers from a DLBCL-Reminiscent Mouse Lymphoma Model Predict Patient Outcome

Kolja Schleich, Julia Kase, MD, Jan R. Dörr, Saskia Trescher, Animesh Battacharya, Yong Yu, Philipp Lohneis, MD, Dido Lenze, Dorothy Ngo-Yin Fan, Michael Hummel, PhD, Ulf Leser, Clemens A. Schmitt

Blood (2018) 132 (Supplement 1): 2850.

https://doi.org/10.1182/blood-2018-99-118002

Published: 2018

Journal Articles

Therapy‐Induced Senescence Is a Predictor of Treatment Outcome in Acute Myeloid Leukemia

Martin Schönlein, J. Henry M. Däbritz, Dorothy Ngo-Yin Fan, Jana Ihlow, Rolf Schwarzer, Binje Vick, Karsten Spiekermann, Thomas Burmeister, Jörg Westermann, Irmela Jeremias, Clemens A. Schmitt

Blood (2017) 130 (Supplement 1): 1393.

https://doi.org/10.1182/blood.V130.Suppl_1.1393.1393

Published: 2017

Journal Articles

Clonal Hematopoiesis: Cell of Origin, Lineage Repartition and Dynamic Evolution during Chemotherapy

Blood (2017) 130 (Supplement 1): 632.

https://doi.org/10.1182/blood.V130.Suppl_1.632.632

Published: 2017

Journal Articles

DLBCL-Derived NF-κb Mutations Exploit Senescence and Immune Evasion Mechanisms to Promote Myc-Driven Lymphomagenesis

Jens F. Schrezenmeier, Maurice Reimann, Sven Masswig, Liam Childs, PhD, Dorothee Childs, PhD, Philipp Lohneis, MD, Clemens A. Schmitt

Blood (2017) 130 (Supplement 1): 2491.

https://doi.org/10.1182/blood.V130.Suppl_1.2491.2491

Published: 2017

Journal Articles

Mouse Lymphoma Model-Based Senescence Exploitation to Predict Treatment Outcome of DLBCL Patients

Kolja Schleich, PhD, Julia Kase, MD, Jan R. Dörr, Saskia Trescher, Animesh Battacharya, Yong Yu, Philipp Lohneis, MD, Dido Lenze, Dorothy Ngo-Yin Fan, Michael Hummel, PhD, Ulf Leser, Clemens A. Schmitt

Blood (2017) 130 (Supplement 1): 5133.

https://doi.org/10.1182/blood.V130.Suppl_1.5133.5133

Published: 2017

Journal Articles

Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma

Blood (2017) 129 (1): 71–81.

https://doi.org/10.1182/blood-2016-02-700773

Published: 2017

Includes: Supplemental data

Journal Articles

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

Larry Mansouri, Daniel Noerenberg, Emma Young, Elena Mylonas, Maysaa Abdulla, Mareike Frick, Fazila Asmar, Viktor Ljungström, Markus Schneider, Kenichi Yoshida, Aron Skaftason, Tatjana Pandzic, Blanca Gonzalez, Anna Tasidou, Nils Waldhueter, Alfredo Rivas-Delgado, Maria Angelopoulou, Marita Ziepert, Christopher Maximilian Arends, Lucile Couronné, Dido Lenze, Claudia D. Baldus, Christian Bastard, Jessica Okosun, Jude Fitzgibbon, Bernd Dörken, Hans G. Drexler, Damien Roos-Weil, Clemens A. Schmitt, Helga D. Munch-Petersen, Thorsten Zenz, Martin-Leo Hansmann, Jonathan C. Strefford, Gunilla Enblad, Olivier A. Bernard, Elisabeth Ralfkiaer, Martin Erlanson, Penelope Korkolopoulou, Magnus Hultdin, Theodora Papadaki, Kirsten Grønbæk, Armando Lopez-Guillermo, Seishi Ogawa, Ralf Küppers, Kostas Stamatopoulos, Niki Stavroyianni, George Kanellis, Andreas Rosenwald, Elias Campo, Rose-Marie Amini, German Ott, Theodoros P. Vassilakopoulos, Michael Hummel, Richard Rosenquist, Frederik Damm

Blood (2016) 128 (23): 2666–2670.

https://doi.org/10.1182/blood-2016-03-704528

Published: 2016

Includes: Supplemental data

Journal Articles

Restoring the Lost B-Cell Phenotype Renders Classical Hodgkin's Lymphoma Susceptible to B-Cell-Targeting Therapies

Nina Rosa Neuendorff, MD, Jing Du, PhD, Yong Yu, PhD, Jens Peter von Kries, PhD, Stephan Mathas, MD, Bernd Dörken, Prof., Soyoung Lee, PhD, Clemens A. Schmitt, MD Prof

Blood (2016) 128 (22): 1094.

https://doi.org/10.1182/blood.V128.22.1094.1094

Published: 2016

NARROW

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma

Therapy-Induced Senescence As an Anti-Cancer and Immune-Stimulatory Strategy

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Senescence Markers from a DLBCL-Reminiscent Mouse Lymphoma Model Predict Patient Outcome

Therapy‐Induced Senescence Is a Predictor of Treatment Outcome in Acute Myeloid Leukemia

Clonal Hematopoiesis: Cell of Origin, Lineage Repartition and Dynamic Evolution during Chemotherapy

DLBCL-Derived NF-κb Mutations Exploit Senescence and Immune Evasion Mechanisms to Promote Myc-Driven Lymphomagenesis

Mouse Lymphoma Model-Based Senescence Exploitation to Predict Treatment Outcome of DLBCL Patients

Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

Restoring the Lost B-Cell Phenotype Renders Classical Hodgkin's Lymphoma Susceptible to B-Cell-Targeting Therapies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only